Open for Enrollment Soon
This study will open for enrollment soon. Please contact the study team for more information and check back frequently.

Telisotuzumab Adizutecan for MET amp solid - Clinical Trial

What is the Purpose of this Study?

What happens during the study?

- You'll get the study medicine through an IV every 3 weeks

- Doctors will take blood and urine samples

- You'll have regular CT or MRI scans to check your health

What is the Condition Being Studied?

Locally advanced or metastatic solid tumors that harbor MET amplification

Who Can Participate in the Study?

Who can join this study?

- Adults who are 18 or older

- Have a type of cancer that has spread and shows a special change called MET amplification

- Have already tried at least one treatment for their cancer

- Don’t have any other good treatment options that are likely to help them live longer

Age Group
Adults

What is Involved?

Why is this study happening?

Doctors are testing a new medicine called Telizotuzumab Adjzutecan (ABBV-400) to see if it is safe and works well for people with certain types of cancer that have spread and have a special change in their cells called MET amplification.

Study Details

Full Title
A Phase 2 Study to Evaluate the Safety and Efficacy of Telisotuzumab Adizutecan for the Treatment of Subjects with Locally Advanced or Metastatic Solid Tumors that Harbor MET Amplification [M25-279]
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00118702
NCT: NCT07196644
Phase
Phase II
ClinicalTrials.gov
Enrollment Status
Open for Enrollment Soon